Kairos Pharma (NYSE:KAPA) announced the presentation of positive preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research and Immuno-Oncology (ACCR IO) conference this month.
According to Kairos, the presentation underscored positive preclinical outcomes with its glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist KROS 101 in melanoma and glioblastoma, as well as its peptide inhibitor for macrophages KROS 401 in glioma animal models.
Dr. John Yu, CEO of Kairos, and co-inventor, commented, “ We continue to receive validation of our preclinical data demonstrating our KROS platform’s development of anti-tumor therapies. KROS 101 addresses an Achilles’ heel of all T cell immunotherapies and that is the development of exhaustion in anti-tumor T cells. KROS 101 appears to prevent the development of exhaustion by T cells enabling them to continue to kill tumor cells.”
Dr. Ram Murali, VP of research and development at Kairos, added, “KROS 401 is designed to reverse the M1 and M2 transition of macrophages in the tumor microenvironment. What this translates to is changing pro-tumor macrophages into anti-tumor macrophages. This leads to tumor-killing activity by both macrophages and T cells.”
